|

Secukinumab Clinical Trials

5 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Also known as: AIN457, Cosentyx, N/A (Not applicable)

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Novartis Pharmaceuticals3
  • NYU Langone Health1
  • NHS Greater Glasgow and Clyde1

Indications

  • Arthritis5
  • Rheumatic Disease1
  • Pediatric Plaque Psoriasis1
  • Juvenile Psoriatic Arthritis1
  • Psoriatic Plaque1

Other3 trials

Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

Gainesville, Florida1 trial

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

University of Florida

Phase 1

New York, New York1 trial

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NYU Langone Health

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.